Compare GAME & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAME | VERU |
|---|---|---|
| Founded | 2011 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 48.2M |
| IPO Year | 2024 | 1996 |
| Metric | GAME | VERU |
|---|---|---|
| Price | $0.44 | $2.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 1.4M | ★ 5.2M |
| Earning Date | 04-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $44,999,302.00 | $16,296,958.00 |
| Revenue This Year | $87.12 | N/A |
| Revenue Next Year | $21.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.24 | $0.36 |
| 52 Week High | $2.87 | $7.33 |
| Indicator | GAME | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 51.87 | 52.97 |
| Support Level | $0.44 | $2.15 |
| Resistance Level | $0.49 | $3.68 |
| Average True Range (ATR) | 0.04 | 0.67 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 51.74 | 15.52 |
GameSquare Holdings Inc is a vertically integrated digital media, entertainment, and technology company focused on gaming and youth culture audiences. The company operates through four reportable segments: Owned and Operated IP, Agency, SaaS and managed services, and Yield. It provides services including influencer marketing, esports talent management, creative production, merchandise and consumer products, live streaming analytics, and digital media solutions through its various brands and platforms. It generates the majority of its revenue from the Agency segment.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.